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ABSTRACT   
 
Introduction:  The gain-of-function mutations that underlie sodium channel myotonia(SCM) 
and paramyotonia congenita(PMC) produce differing clinical phenotypes. We used muscle 
velocity recovery cycles (MVRCs) to investigate membrane properties.  
Methods:  MVRCs and responses to trains of stimuli were compared in patients with SCM 
(n=9), PMC (N=8), and normal controls (n=26). 
Results:  The muscle relative refractory period was reduced in SCM, consistent with faster 
recovery of the mutant sodium channels from inactivation. Both SCM and PMC showed an 
increased early supernormality, and increased mean supernormality following multiple 
conditioning stimuli, consistent with slowed sodium channel inactivation. Trains of fast 
impulses caused a loss of amplitude in PMC, after which only half of the muscle fibres 
recovered, suggesting that the remainder stayed depolarized by persistent sodium currents.  
Discussion:  The differing effects of mutations on sodium channel function can be 
demonstrated in human subjects in vivo using this technique.  
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INTRODUCTION 
Mutations in the transient sodium channel Nav1.4 underlie both sodium channel 
myotonia (SCM) and paramyotonia congenita (PMC).  
Patients with SCM typically have myotonic stiffness following muscle contraction, 
which improves with repetition (the ‘warm-up’ phenomenon) and do not have exercise- or 
cold-induced weakness. These patients may sometimes demonstrate mild worsening of 
stiffness with repeated muscle contraction (paradoxical myotonia), particularly with forced 
eye closure, before subsequently showing the typical ‘warm-up’ phenomenon. 
Patients with PMC typically have paradoxical myotonia as well as exercise-related 
weakness, particularly with muscle exertion at cold temperatures. With warming, this 
weakness does not resolve immediately, and when severe, may take several hours to 
recover. Some patients may also have exercise-induced weakness at room temperature.  
The sodium channel mutations in both conditions produce a gain-of-function 
abnormality due to disrupted inactivation or enhanced activation. Slowed fast inactivation 
increases the action potential duration, which increases the potassium efflux into the t-
tubules, resulting in a larger after-depolarisation following each action potential which, 
when sufficient, triggers spontaneous action potentials leading to a train of myotonic 
discharges
1
 .  
In some PMC mutations, there is often an additional problem disrupting the final 
extent of inactivation, as well as a cold-induced left shift of the activation curve causing a 
greater, and more persistent, inward sodium current leading to more marked depolarisation 
and consequent weakness
2
.   It would be helpful if these membrane abnormalities could be 
reliably studied in vivo, particularly as a potential tool for assessing the efficacy of any 
treatment interventions.  A convenient, though necessarily indirect, method of inferring 
changes in muscle fibre membrane properties in vivo is to measure how the velocity of a 
muscle action potential depends on the time interval after a preceding action potential, i.e. 
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the muscle velocity recovery cycle (MVRC)
3
.  Immediately after an action potential the 
muscle fibre is refractory, and then, during the muscle relative refractory period (MRRP) a 
second impulse is conducted more slowly.  Following the MRRP, there is a supernormal 
period, when action potentials are conducted faster than normal, which lasts at least a 
second.  The supernormal period comprises two functional components: early 
supernormality (ESN), which is related to an early depolarizing afterpotential, and late 
supernormality (LSN), which is related to a late depolarizing afterpotential, and unlike ESN is 
increased by multiple conditioning impulses.  Like superexcitability in nerve, ESN in muscle is 
strongly dependent on membrane potential and sodium channel gating, since they depend 
primarily on the excess of inward sodium charge movement over outward potassium charge 
movement during the action potential.  LSN has no equivalent in nerve, and is thought to 
relate to potassium accumulation in the t-tubule system
3
 .   
MVRCs, comprising MRRP, ESN and LSN, can be reliably measured in human muscles 
by direct stimulation and recording of a bundle of adjacent muscle fibres with a sequence of 
paired electrical pulses of equal amplitude and varying interstimulus interval (ISI)
3-5
.  They 
indicate a rapid onset of membrane depolarization during limb ischemia
3
 and have been 
used to infer muscle membrane depolarization in renal failure
6
 and to provide information 
about membrane abnormalities in critical illness myopathy
7
, Andersen-Tawil syndrome
8
, 
myotonia congenita
9
 and myotonic dystrophy
10
. 
In this study we have used MVRCs, supplemented by two previously described 
repetitive stimulation protocols
11
 , to investigate the muscle membrane abnormalities in 
SCM and PMC.  Our aim was to determine if these new methods could provide new insights 
into the pathophysiology of these sodium channelopathies, or provide new measures that 
could be useful as biomarkers. 
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METHODS 
Patients  
There were 9 patients with SCM and 8 with PMC (Table 1).   The SCM patients were aged 
45.6 ± 13.6 years (mean ± SD, range 22-67) and the PMC patients were aged 46.8 ± 18.4 
years (range 21 to 72).  All were genetically confirmed. The patients with PMC all had the 
same common Thr1313Met mutation, and 5 of the SCM patients had the Val1589Met 
mutation.  
Asymptomatic Controls  
The MVRC studies were compared with recordings from 26 healthy volunteers, 10 men, 16 
women, aged 44.2 ± 12.3 years (range 27-66) who served as normal controls (NC). 
Consent 
Informed written consent was obtained from all patients and controls according to the 
Declaration of Helsinki. This study was approved by the St Thomas’ Hospital Research Ethics 
Committee, London, UK.   
 
Study Protocol 
All the patients had standard nerve conduction studies, muscle velocity recovery studies, the 
short exercise test at room temperature, and a blood sample for electrolytes and glucose 
taken on the same day.  
 
Short Exercise Test 
 
Short exercise tests (SETs) were performed by stimulating the ulnar nerve at the wrist and 
recording with surface electrodes over the abductor digiti minimi. Compound muscle action 
potentials (CMAPs) were recorded at baseline and every 10s during 3 short exercise trials 
(10s exercise followed by 60s rest). The amplitude changes from baseline were calculated 
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and plotted as described previously
12
.   The SET Pattern was given a number as described by 
Fournier and colleagues
13
 -   Pattern 1 : Decrement without recovery during the 60s rest 
period, typically worsening with consecutive exercise trials; Pattern 2: Transient decrement 
with recovery during each 60s rest period; often becoming less marked with subsequent 
exercise trials; Pattern 3: no decrement. 
 
Muscle velocity recordings  
Experimental setup 
The recording technique was as described previously for tibialis anterior (TA)
8-10
, and will be 
briefly summarized below. For details of the muscle velocity recovery cycle and ramp 
protocols, please see Tan et al 2014
9
, and for details of the repetitive stimulation protocol, 
please see Tan et al 2012
8
.    
Recordings were performed from the distal third of TA. Stimuli consisting of 0.05 ms 
rectangular current pulses were delivered through an insulated monopolar needle electrode 
with a surface electrode as anode. Muscle activity was recorded by means of a concentric 
needle electrode approximately 20 mm proximal to the stimulating needle.  Patients were 
studied in a heated room and kept warm in an effort to achieve a skin temperature as near as 
possible to 32 deg C at the start of the study. Surface temperature over TA was recorded at 
the end of the recording.  
The signal was amplified (gain 300-1000, bandwidth 0.2 Hz to 3 kHz) and digitized 
(NIDAQ-6062E, National Instruments Europe Corp.) using a sampling rate of 20 kHz. The 
needle electrodes were adjusted to obtain a stable negative peak response with a stimulus of 
3-10 mA. Stimulation and recording were controlled by Qtrac software (written by H. 
Bostock, Institute of Neurology, London, UK), using the 1200RCMQ.QRP recording protocol. 
 
Muscle Velocity recovery cycles (MVRCs) at rest 
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MVRCs were recorded following 1, 2, and 5 conditioning stimuli (10 ms apart). Test stimuli 
were delivered every 2s. The inter-stimulus interval (ISI) between the last conditioning 
stimulus and the test stimulus was reduced from 1000 to 1.4 ms in 34 steps in an 
approximately geometric series.  
 
Frequency ramp.   
In order to characterize the effects of progressive muscle activation, a 1-sec train of stimuli 
was delivered every 2 sec, with the number of stimuli in the train increased (ramped up in 
frequency) by 1 from 2 to 31 in successive 2-sec cycles
11
.  During the frequency ramp, the 
mean stimulation rate increased from 1 to 15.5 Hz over 1 minute, and responses were 
measured to the first and last stimuli in each train.   Stimulus cycles with the test stimulus 
alone were recorded before the frequency ramp (10 cycles at 0.5Hz) and for 30 sec after the 
end of the ramp (15 cycles at 0.5 Hz).  
 
Repetitive stimulation.  
The effects of intermittent high frequency electrical stimulation on muscle membrane 
properties was studied by recording repeated short (18-step) MVRCs and then interleaving 
the conditioning and test stimuli with 1s trains of stimuli at 20 Hz as previously described in 
detail
8,11
.  Four MVRCs  were initially recorded at rest (each providing estimates of MRRP and 
ESN), then 5 MVRCs were measured during intermittent 20 Hz stimulation for 6 minutes, and 
further MVRCs were recorded during recovery for at least 5 minutes. 
 
Data analysis 
 Recovery cycle data were analyzed by the QtracP program, as previously 
described
3,4
. After filtering the responses, latencies were measured from the start of the test 
stimulus to the negative peak of the muscle action potential. The effects of 1, 2, and 5 
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conditioning pulses on the latency of the test response were calculated as percentage 
differences compared to the responses to the test stimulus alone.  
The following excitability measures were derived from the 3 recording protocols: 
a) MVRCs at rest. The MRRP was defined as the earliest (interpolated) ISI at which the 
latencies of the conditioned and unconditioned test responses were identical.  Early 
supernormality (ESN) was measured as the largest percentage decrease in latency for ISIs 
below 15 ms.  Late supernormality (LSN) was the mean percentage decrease in latency for 
ISIs between 50 and 150 ms.  We defined ‘supernormality at 20 ms’ (SN20) as the mean of 
supernormalities at 18 and 22 ms, 5ESN as the early supernormality after 5 conditioning 
impulses, and ‘residual supernormality’ (RSN) as the mean percentage decrease in latency at 
the end of the sweep, averaged for ISIs of 900 and 1000 ms. MSN is mean supernormality, 
i.e. average latency reduction between RRP and 1 sec, corresponding to area under curve 
when plotted with linear ISI axis. We also defined the ‘extra’ supernormalities 5XLSN, 
5XMSN, and 5XRSN as the differences between the percentage latency decreases for 5 and 1 
conditioning stimuli.  Supernormality to 5 conditioning stimuli at 20ms’ (5SN20) was defined 
as the mean of supernormalities at 18 and 22ms to 5 conditioning stimuli. 
In our earlier study of MC patients, we found that those on mexiletine were distinguished by 
having significantly smaller values of 5ESN (early supernormality after 5 conditioning pulses)
 
9
.  To check whether inclusion of these patients was materially affecting the results, we 
compared 5ESN values inclusive and exclusive of these patients.   
 b) Frequency ramp.  We measured the latency of the negative peak of the muscle action 
potential, expressed as a percentage of baseline latency, at 15Hz [Lat(15Hz)] and 30Hz 
[Lat(30Hz)] during the ramp, and 30s after the end of the ramp Lat(30Hz+30s)%.   During the 
ramp, responses to the first and last stimuli in the train were designated with the subscript 
First or Last respectively. 
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c) Repetitive stimulation. The MVRC measurements taken during intermittent 20 Hz 
stimulation were: changes in peak amplitude and latency, MRRP and ESN.  These values were 
averaged for the first two (1,2) and the last two (4,5) cycles of intermittent 20 Hz stimulation, 
and for cycles 1-3 during recovery after the end of repetitive stimulation. 
 
Statistics 
We used the Welch rank test (non-parametric unequal variance t-test) for intergroup 
comparisons.  When comparing groups with multiple comparisons or correlations, only 
P<0.01 was considered significant, but for discussion, P<0.05 is mentioned when relevant for 
individual tests.  
 
RESULTS 
Nerve conduction studies   
None of the patients had evidence of a generalised large fibre neuropathy. 
Short exercise test 
The results of the SETs at room temperature are detailed in Table 1.  The SET 
performed on the day of the muscle excitability studies showed a progressive decrement 
typical of PMC (Pattern 1) in 6 of 8 patients with PMC. Two patients with SCM showed a 
fluctuating decrement which did not correspond to Patterns 1 or 2. The remaining patients 
showed no abnormal decrement (Pattern 3). 
 
Velocity recovery cycles 
The results of the MVRCs with 1, 2 and 5 conditioning stimuli are illustrated in Figure 
1, and the measurements are compared in Table 2.  The most striking feature, which is 
common to both SCM and PCM patients, is an increase in supernormality which becomes 
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more pronounced and prolonged by additional conditioning stimuli, so that with 5 
conditioning stimuli there are highly significant increases, compared with controls, in early 
supernormality (5ESN), and also in the extra late supernormality (5XLSN) and extra mean 
supernormality over 1s (5XMSN) compared with a single conditioning impulse.  The 
differences between SCM and PMC on the one hand, and MC on the other, were most 
marked in the case of the extra residual supernormality at 900-1000ms (5XRSN: NC = 1.0%, 
SCM and PMC = 1.7%, MC = 2.8%). 
The main difference between the recovery cycles of SCM and PMC patients was in 
their relative refractory period (MRRP), and time to peak supernormality (ESN@).  In this 
respect the SCM patients showed a significantly quicker post-spike recovery of excitability 
than either the controls or the PMC patients.   
In this study only one SMC patient and 1 PMC patient were under the influence of 
mexiletine at the time of the recordings.  In both cases, 5ESN values for the patient on 
mexiletine were actually above the average of the others, and mean values were not 
appreciably affected: SMC 16.9 including and 16.7 excluding mexiletine; PMC 15.5 including 
and 15.2 excluding mexiletine; all values well above 13.0 for the normal controls.  Because of 
the limited numbers of patients, and the absence of any clear effect of mexiletine, the two 
patients on mexiletine were included in the remaining analyses. 
 
 
Frequency Ramp 
 The results of increasing the stimulation rate up to an average of 15.5 Hz, by adding 
intermittent 1s trains of conditioning stimuli at frequencies from 1 to 30 Hz are illustrated 
for an SCM patient in Figure 2A, for a PMC patient in Figure 2B, and the average changes in 
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latency and peak amplitude compared with the normal control subjects in Figure 3 and Table 
3.   
   This stimulation protocol produced only modest changes in amplitude for the SCM 
patients, as for the controls (Figs. 2A and 3).  In contrast there were marked changes in the 
PMC group, in all of whom the amplitude of the responses dropped during the ramp and 
only partially recovered afterwards, as shown in Figs. 2B and 3.  Because of the almost 
complete loss of amplitude during the high-frequency trains, it was not possible to measure 
latencies for most of the PMC patient for the last action potential in each train for the latter 
part of the frequency ramp.  There was, however, always some recovery by the time the next 
train started 1s later, so latencies for the first action potential in each train were always 
measurable. 
   In the SCM group, the main difference from the controls was a greater reduction in latency 
at 15Hz, especially at the end of the 15Hz train, indicating a greater than normal 
depolarisation.   
 
Repetitive stimulation 
 
The results of interspersing a 1 s train of 20 stimuli between recovery cycle 
measurements for a period of 6 m are illustrated in Figure 4 and measurements listed in 
Table 4.   As with the frequency ramp, the most conspicuous abnormality was seen in the 
responses of the PMC patients, which suffered a severe loss of amplitude when the 20 Hz 
trains were started, which made the latencies of many of the subsequent responses 
unmeasurable. 
In the SMC group, the abnormally short RRPs and high ESN values were maintained 
throughout the period of repetitive stimulation.  The most distinctive feature was a failure to 
show the normal decrease in supernormality during the repetitive stimulation, so that the 
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most significant abnormality in our recordings from these patients was the value of ESN 
during cycles 4 and 5 . 
 
Separation of myotonia subtypes 
Supplementary Figure 1 explores the potential use of the various MVRC and other 
measurements to distinguish between the different types of myotonia studied so far.  
Supplementary Figure 1A shows that the drop in amplitude of the muscle action potentials 
during the frequency ramp separates the PMC patient from the other groups, including the 
previously studied 11 MC patients that were not on medication
9
.  Combinations of MVRC and 
frequency ramp measurements provided separation between the 3 myotonia subtypes 
(Supplementary Figure 1B) or between PMC, MC and normal controls (Supplementary Figure 
1C).  In most measurements there was considerable overlap between the SMC and NC 
groups, and combinations of MVRC, frequency ramp and repetitive stimulation 
measurements were needed to separate them (Supplementary Figure 1D).   
  
DISCUSSION 
Conduction changes related to myotonia and weakness 
 We have previously reported that in myotonia congenita (MC) the lack of functional 
chloride channels results in increased early, late and residual supernormality, indicating an 
enhanced depolarizing afterpotential, which increases and becomes prolonged with trains of 
impulses
9
.  These changes are in the direction expected to facilitate repetitive myotonic 
discharges, although such activity was not detected in the small columns of muscle fibres 
studied.  Rather similar increases in early, late and residual supernormality were seen in both 
the SCM and PMC groups of patients.  Although less pronounced than in MC, (e.g. 5XLSN: NC 
= 7.0%, SCM and PMC = 9.1%, MC = 10.1%;  5XMSN: NC = 3.5%, SCM and PMC = 4.4%, MC = 
Page 17 of 30
John Wiley & Sons, Inc.
Muscle & Nerve
This article is protected by copyright. All rights reserved.
  1414 
5.8% ) it seems reasonable to conclude that the enhanced depolarizing afterpotentials that 
give rise to the supernormality provide the trigger for myotonia in these patients also.  
Since MRRP and ESN@ are strongly temperature-dependent, it is important to note 
that the skin temperatures recorded in the SCM patients (30.2 ± 0.4˚C, mean ± SE) were no 
warmer than those in the controls (30.4 ± 0.2˚C) or the PMC patients (30.6 ± 0.7˚C).  
In our previous study on MC patients
9
, Mexiletine was associated with a reduced 
5ESN. In this study, the SCM and PMC patient on Mexiletine each had 5ESN values above the 
average in their respective groups. One possible explanation for the difference being in the 
opposite direction to that expected compared with the patients not on Mexiletine, is that the 
two patients taking regular mexiletine were particularly clinically symptomatic, and it is 
possible that their symptoms reflected the degree of channel dysfunction, and therefore 
even treatment with mexiletine did not result in reduction of the 5ESN below the mean for 
the rest of the group.  
 Weakness is a feature of PMC but not of SCM.  Whereas very little difference is seen 
between these two groups in the effects of 1 to 5 conditioning stimuli, the biophysical basis 
for the weakness in PMC is clearly seen in the effects of the frequency ramp and repetitive 
stimulation in Figs. 2 - 4.  In all 8 patients there was a similar rapid decline in amplitude of 
the muscle action potentials at frequencies above about 10 Hz.   The lack of full recovery in 
the amplitude after the end of the ramp accounts for the weakness that can continue in PMC 
patients following exercise.  Since the latency returned to normal, it appears that the 
population of muscle fibres was split by the frequency ramp: about half the fibres recovered 
to normal resting potential, while the remainder stayed sufficiently depolarized to be 
inexcitable.  This bistability of the membrane potential can be explained by the sodium 
channel mutation, as discussed below. 
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 Unlike the SET at room temperature, where 2 of the 8 PMC patients failed to show an 
abnormality, the frequency ramp demonstrated a clear abnormality in all 8 of these patients, 
as did the later intermittent stimulation at 20 Hz. 
 
Relationship of conduction changes to sodium channel mutations 
The larger ESN, indicating an increased depolarizing afterpotential, in both SCM and 
PMC groups is consistent with a lengthened duration of the muscle action potential due to a 
slower rate of entry into inactivation (SCM and PMC), and slowed deactivation in SCM
14-16
.  In 
spite of this, the relative refractory period (MRRP) was significantly shorter than normal in 
the SCM group.  This can be explained by the faster recovery of the mutant sodium channel 
from inactivation, which has been found for Val1589Met mutations (the most common 
among our SCM patients) expressed in human embryonic kidney cells in vitro7.  In the case 
of the PMC patients, their Thr1313Met mutation has been reported to induce both slowed 
inactivation
18
 and faster recovery from inactivation
16
 and these effects appear to largely 
cancel out. 
The most striking differences between the SCM and PMC mutations was in their 
effects on repetitive stimulation in the frequency ramp.  At high frequencies the PMC muscle 
fibres became depolarized to inexcitability, and after the train only about half the fibres 
recovered their membrane potential, as discussed above.  In the fibres that remained 
depolarized, a continuous source of depolarizing current, sufficient to outweigh the 
repolarizing potassium and chloride currents, was presumably provided by the mutant 
sodium channels.  Consistent with this, all the PMC patients in this study had the 
Thr1313Met mutation, which has been shown by in vitro heterologous expression 
experiments to generate unusually large persistent (non-inactivating) sodium currents
16
.  The 
persistent sodium currents are regenerative, and enable the muscle fibres to exist in two 
Page 19 of 30
John Wiley & Sons, Inc.
Muscle & Nerve
This article is protected by copyright. All rights reserved.
  1616 
stable states: either at a normal resting potential with the currents switched off, or held 
depolarized and inexcitable by strongly activated persistent currents.   It seems that the 
muscle fibres that recovered from the frequency ramp protocol were not inherently resistant 
to this regenerative depolarization, since when they were subjected to a further bout of 
repetitive stimulation with the intermittent 20 Hz protocol (which always followed the 
frequency ramp), there was a further substantial drop in amplitude, which was again 
irreversible for the duration of the experiment (Fig. 4C).  
 
In conclusion, although it is of interest that multiple measurements are able to separate 
different myotonia subtypes, we do not advocate the use of these techniques as a diagnostic 
utility.  Muscle channelopathy gene panels have become increasingly more widely available 
and affordable, and there is a decreasing requirement for electrodiagnostic guides to genetic 
testing. Instead, the strength of these techniques is in providing a means of studying the 
effects of the muscle ion channel mutations in vivo.  In this study, we have found that 
abnormalities in mutant sodium channel function can be demonstrated in vivo in human 
subjects using muscle excitability studies.  In earlier publications
8-10
 we have shown that 
alterations in chloride and potassium channel function are also demonstrable using this 
stimulation paradigm. The method is minimally invasive (the stimulation setup is similar to 
stimulated single fibre EMG studies), relatively painless, and can be easily repeated in the 
same individual over time.  It is therefore suitable for use as a biomarker in future treatment 
trials.  
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Abbreviations 
CMAP: compound muscle action potential 
ESN: early supernormality 
ISI: inter-stimulus interval 
LSN: late  supernormality 
MC: myotonia congenita 
MRRP: muscle relative refractory period 
MSN: mean supernormality  
MVRC: muscle velocity recovery cycle 
PMC: paramyotonia congenita 
RSN: residual supernormality 
SET: short exercise test 
SCM: sodium channel myotonia 
SN20: Supernormality at 20ms (mean of supernormalities at 18 and 22 ms)  
TA: tibialis anterior 
5ESN: early supernormality after 5 conditioning stimuli 
5SN20: Supernormality at 20ms after 5 conditional stimuli 
5XMSN: extra mean supernormality after 5 conditioning stimuli 
5XLSN: extra late supernormality after 5 conditioning stimuli 
5XRSN: extra residual supernormality after 5 conditioning stimuli 
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Table 1. Myotonias due to sodium channel mutations:  list of patients 
 
 
 
Pt 
 
SET  
Pattern 
SET RT 
Abnormal 
(Y/N) # 
Max amp 
decrement 
(%) Diag Gene 
Amino 
acid 
change Gender Age 
Rx Rx 
1 1 Y 77 PMC SCN4A Thr1313Met M 55 Mexiletine  + 
2 1 Y 64 PMC SCN4A Thr1313Met F 42 None - 
3 1 Y 28 PMC SCN4A Thr1313Met M 68 (Mexiletine) ‡   - 
4 1 Y 49 PMC SCN4A Thr1313Met M 72 None - 
5 3 N 9 PMC SCN4A Thr1313Met M 49 (Mexiletine) - 
6 1 Y 31 PMC SCN4A Thr1313Met M 41 (Mexiletine) - 
7 1 Y 78 PMC SCN4A Thr1313Met F 21 None - 
8 3 N 9 PMC SCN4A Thr1313Met M 25 None - 
9 3 N 0 SCM SCN4A Val1589Met M 45 None - 
10 3† ? 16 SCM SCN4A Val1293Ile M 40 (Mexiletine) - 
11 3 N 0 SCM SCN4A Gly1306Ala F 36 (Mexiletine) - 
12 3 N 1 SCM SCN4A Gly1306Ala M 67 Mexiletine  + 
13 3 N 0 SCM SCN4A Leu128Pro F 56 (Mexiletine) - 
14 3 N 2 SCM SCN4A Val1589Met F 57 None - 
15 3† ? 40 SCM SCN4A Val1589Met M 37 Quinine + 
16 3 N 0 SCM SCN4A Val1589Met F 50 None  - 
17 3 N 0 SCM SCN4A Val1589Met M 22 None - 
 
 
 
Pt: patient; SET RT: short exercise test at room temperature; Y:yes; N:no; max: maximum; 
amp: amplitude; Diag: diagnosis; TW: transient weakness; PMC: paramyotonia congenita; 
SCM: sodium channel myotonia.  # Upper limit of normal for amplitude-only decrement at 
room temperature = 11.5% (Tan et al, 2011).  † FluctuaWng decrement with no clear paXern 
of change (did not ﬁt paXerns 1 or 2). ‡MedicaWon in parentheses and Rx designated ‘-‘ if the 
medication had been omitted for >5 times the half life (T
½
) of the drug at the time of the 
study (T
1/2
 mexilitine 10-12 h, T
1/2 
quinine sulfate 12-18 h,). 
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Table 2. Velocity recovery cycle measurements compared between the three groups. 
 
 
(Mean ± SE) (P for Welch rank test) 
 NC 
(n = 26) 
SCM 
(n = 9) 
PMC 
(n = 8) 
NC v 
SCM 
NC v 
PMC 
SCM v 
PMC 
MRRP (ms) 3.70 ± 0.12 3.05 ± 0.13 3.83 ± 0.11 0.0045 0.11 0.0007 
ESN (%) 11.19 ± 0.44 13.37 ± 0.61 12.25 ± 0.48 0.0076 0.087 0.18 
ESN@ (ms) 7.98 ± 0.23 6.94 ± 0.24 8.92 ± 0.35 0.0088 0.038 0.00015 
5ESN (%) 13.01 ± 0.53 16.91 ± 0.52 15.53 ± 0.65 1.7×10-5 0.0068 0.17 
SN20 (%) 6.44 ± 0.28 7.57 ± 0.34 8.25 ± 0.28 0.018 6.4×10
-6
 0.40 
5SN20 (%) 12.25 ± 0.52 14.88 ± 0.71 15.39 ± 0.72 0.0063 0.0018 0.71 
LSN (%) 3.68 ± 0.17 3.91 ± 0.25 4.46 ± 0.31 0.40 0.052 0.18 
5XLSN (%) 7.03 ± 0.31 9.12 ± 0.50 9.14 ± 0.32 0.0016 0.00060 0.89 
MSN (%) 1.28 ± 0.05 1.29 ± 0.08 1.362± 0.10 0.89 0.015 0.023 
5XMSN (%) 3.40 ± 0.15 4.39 ± 0.32 4.36 ± 0.12 0.0056 9.7×10-5 1.00 
RSN (%) 0.13 ± 0.04 -0.11 ± 0.08 0.23 ± 0.79 0.0096 0.037 0.0029 
5XRSN (%) 0.99 ± 0.08 1.72 ± 0.29 1.71 ± 0.24 0.019 0.0017 0.89 
 
 
  
NC = normal controls.  SCM = sodium channel myotonia.  PMC = paramyotonia congenital. 
MRRP = muscle relative refractory period. ESN = early supernormality (up to 15 ms). ESN@ = 
inter-stimulus interval for maximum ESN. SN20 = supernormality at 20 ms. 5SN20 = SN20 
after 5 conditioning stimuli. LSN = late supernormality (50-150 ms). MSN = mean 
supernormality (up to 1 s). RSN = residual supernormality (900-1000 ms). 5XLSN etc = extra 
supernormality after 5 conditioning stimuli compared with 1 conditioning stimulus. P values 
of <0.01 are in bold type. Values listed are means ± standard errors of the mean.  
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Table 3. Frequency ramp measurements compared between the three groups. 
 
 
(Mean ± SE) (P for Welch rank test) 
 NC 
(n = 25) 
SCM 
(n = 9) 
PMC 
(n = 8) 
NC v 
SCM 
NC v 
PMC 
SCM v 
PMC 
Lat(15Hz)First%              94.0 ± 0.6 92.2 ± 0.6 93.0 ± 1.1 0.014 0.35 0.35 
Lat(15Hz)Last% 84.8 ± 0.7 80.7 ± 0.6 81.8 ± 1.1 0.00015 0.039 0.75 
Lat(30Hz)First%              94.9 ± 0.7 93.5 ± 1.3 104.4 ± 2.4 0.35 6.2×10
-7
 9.3×10
-6
 
Lat(30Hz)Last%              89.0 ± 1.1 83.7 ± 1.7 - 0.032 - - 
Lat(30Hz+30s)%           101.7 ± 0.3 102.2 ± 0.7 101.4 ± 1.9 0.85 0.78 0.89 
Pk(15Hz)First% 111.5 ± 2.4 109.2 ± 5.9 96.6 ± 9.1 0.71 0.18 0.35 
Pk(30Hz)First% 115.0 ± 2.9 116.5 ± 10.5 39.6 ± 6.4 0.73 4.6×10
-10
 9.5×10
-6
 
Pk(30-15Hz)First% 3.4 ± 1.8 7.3 ± 5.3 -57.0 ± 11.6 0.79 1.2×10
-9 9.5×10-6 
Pk(30Hz)Last% 87.5 ± 5.1 86.1 ± 18.4 3.5 ± 5.4 0.66 1.2 ×10
-9 6.0×10-5 
Pk(30Hz+30s)% 104.5 ± 2.2 110.3 ± 6.3 50.5 ± 7.6 0.70 2.6×10-9 9.5×10-6 
 
  Lat(15Hz)First% = percentage change in latency for first muscle action potential of 15 Hz 
train. Pk(30Hz)Last% = peak amplitude for last action potential in 30Hz train as percentage of 
control. Pk (30-15Hz)First% = difference in peak amplitude of first action potentials at 15 and 
30 Hz. Pk(30Hz+30s)% = peak amplitude 30s after end of 30Hz train. Gaps  for Lat(30Hz)Last%  
are because some of the PMC responses were too small to measure.  Values and statistics are 
as in Table 2. 
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Table 4. Repetitive stimulation measurements compared between the three groups. 
 
 
(Mean ± SE) (P for Welch rank test) 
 NC 
(n = 24) 
SCM 
(n = 9) 
PMC 
(n = 8) 
NC v 
SCM 
NC v 
PMC 
SCM v 
PMC 
Peak (% baseline, start of 20 Hz) 
  Cycles 1,2 106.3 ± 1.6 102.5 ± 6.7 62.1 ± 8.0 0.84 6.2×10
-9
 0.00070 
  Cycles 4,5 99.1 ± 2.9 100.8 ± 10.3 39.8 ± 6.7 0.91 8.3×10
-10
 2.8×10
-5
 
  Recovery 86.8 ± 3.6 86.9 ± 7.0 33.6 ± 7.3 0.67 1.0×10-7 2.8×10-5 
Latency (% baseline, start of 20 Hz) 
  Cycles 1,2 98.6 ± 0.3 98.7 ± 0.6 - 0.90 - - 
  Cycles 4,5 103.1 ± 0.6 102.6 ± 1.1 - 0.82 - - 
  Recovery 102.6 ± 0.4 100.3 ± 0.8 - 0.047 - - 
MRRP (ms) 
  Baseline 3.94 ± 0.16 3.24 ± 0.09 4.64 ± 0.26 0.0010 0.0020 8.8×10
-6
 
  Cycles 1,2              5.91 ± 0.29 4.59 ± 0.33 - 0.016 - - 
  Cycles 4,5              5.48 ± 0.26 4.16 ± 0.23 - 0.0012 - - 
  Recovery           4.04 ± 0.11 3.59 ± 0.14 - 0.013 - - 
ESN (%) 
  Baseline 10.56 ± 0.45 12.87 ± 0.59 8.56 ± 0.86 0.0098 0.079 0.00032 
  Cycles 1,2              7.13 ± 0.46 11.99 ± 1.07 - 0.00064 - - 
  Cycles 4,5              9.03 ± 0.42 12.70 ± 0.63 - 1.4×10
-6
 - - 
  Recovery           10.91 ± 0.41 11.07 ± 0.59 - 0.81 - - 
 
 
 MRRP = muscle relative refractory period. ESN = early supernormality. Gaps occur where 
some PMC responses were too small to measure latencies. Values and statistics are as in 
Table 2. 
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Figure Legends 
FIGURE 1.  Muscle velocity recovery cycles (MVRCs) with 1, 2 and 5 conditioning stimuli. A: 
MVRCs in sodium channel myotonia (SCM, n=9, filled black squares) compared with normal 
controls (NC, n=26, open grey circles). Percentage change in latency is plotted against ISIs 
from 2 to 1000 ms (logarithmic scale).  Inset shows relationship between single conditioning 
(c) and test (t) stimuli. Data points show means with single standard error bar.  B,C: As A, but 
with 2 (2c) and 5 (5c) conditioning stimuli 10ms apart.  D-F: corresponding plots comparing 
paramyotonia congenita patients (PMC, n=8, filled black circles) and normal controls.  
 
FIGURE 2.  Frequency ramp recordings in a patient with sodium channel myotonia (SCM) (A) 
and a patient with paramyotonia congenita (PMC)(B).  In each part the main panel shows the 
responses during the 1s period of stimulation, delivered at intervals of 2s.  The number of 
stimuli in 1s increases from 2 in the top trace to 31 in the penultimate trace, and drops back 
to 1 in the last trace.  To the right of the main panel the responses to the first and last stimuli 
in each train are plotted on expanded time scales.  In these traces the stimulus artefact (a) is 
visible as well as the muscle action potential (m). In the main panels the stimulus artefacts 
are suppressed for simplicity and to reveal the changing amplitudes of the muscle responses 
in the PMC patient more clearly.  
 
FIGURE 3.  Frequency ramp responses of sodium channel myotonia (SCM) and paramyotonia 
congenita (PMC) patients compared with those of normal controls (NC). Solid lines are 
means, dotted lines are means ± standard error.  (A) Normal controls (n=26), (B) Sodium 
channel myotonia patients (n=9) plotted in black with controls in gray (means only), (C) 
Paramyotonia congenita patients (n=8) plotted in black with controls in gray.  Top row: 
latency as percent of baseline for the last response in each train; second row: latency as % 
baseline for the first response in each train; third row:  peak amplitude as % baseline for the 
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last response in each train; fourth row: peak amplitude as % baseline for the first response in 
each train; bottom row: stimulation rate during the train.  Asterisk in C indicates time when 
some muscle action potentials became too small to measure latencies. 
 
FIGURE 4.  Effects of repetitive stimulation on muscle action potential amplitudes, latencies, 
and muscle velocity recovery cycles.  A: Part of sequence of stimulating pulses, showing 
alternation between 1s trains at 20 Hz, conditioning(c) and test(t) pairs, and test stimuli 
alone.  B-D: Average recordings from 26 normal control subjects (NC)(B), 9 patients with 
sodium channel myotonia (SCM)(C), and 8 patients with paramyotonia congenita (PMC)(D). 
Data are reported as mean (continuous line) ± standard error (broken lines).  Comparisons in 
(C) and (D) are against mean control values in gray.  Top two panels: Amplitude changes as a 
percentage of baseline of the first and last responses in the train respectively. Third panel: 
Latencies, expressed as % baseline value. Fourth panel: Relative refractory periods. Bottom 
panel: Peak early supernormality, expressed as % reduction in latency. Bars indicate 6m 
periods of intermittent 20 Hz stimulation. Asterisks in D indicate times when muscle action 
potentials in some PMC patients became too small to measure latencies. 
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FIGURE 1.  Muscle velocity recovery cycles with 1, 2 and 5 conditioning stimuli. A: MVRCs in sodium channel 
myotonia (SCM, n=9, filled black squares) compared with normal controls (NC, n=26, open grey circles). 
Percentage change in latency is plotted against ISIs from 2 to 1000 ms (logarithmic scale).  Inset shows 
relationship between single conditioning (c) and test (t) stimuli. Data points show means with single 
standard error bar.  B,C: As A, but with 2 (2c) and 5 (5c) conditioning stimuli 10ms apart.  D-F: 
corresponding plots comparing paramyotonia congenita patients (PMC, n=8, filled black circles) and normal 
controls.  
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FIGURE 2.  Frequency ramp recordings in a patient with sodium channel myotonia (SCM) (A) and a patient 
with paramyotonia congenita (PMC)(B).  In each part the main panel shows the responses during the 1s 
period of stimulation, delivered at intervals of 2s.  The number of stimuli in 1s increases from 2 in the top 
trace to 31 in the penultimate trace, and drops back to 1 in the last trace.  To the right of the main panel 
the responses to the first and last stimuli in each train are plotted on expanded time scales.  In these traces 
the stimulus artefact (a) is visible as well as the muscle action potential (m).  N.B. In the main panels the 
stimulus artefacts are suppressed for simplicity and to reveal the changing amplitudes of the muscle 
responses in the PMC patient more clearly.  
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FIGURE 3.  Frequency ramp responses of sodium channel myotonia (SCM) and paramyotonia congenita 
(PMC) patients compared with those of normal controls (NC). Solid lines are means, dotted lines are means 
± standard error.  (A) Normal controls (n=26), (B) Sodium channel myotonia patients (n=9) plotted in black 
with controls in gray (means only), (C) Paramyotonia congenita patients (n=8) plotted in black with controls 
in gray.  Top row: latency as percent of baseline for the last response in each train; second row: latency as 
% baseline for the first response in each train; third row:  peak amplitude as % baseline for the last 
response in each train; fourth row: peak amplitude as % baseline for the first response in each train; 
bottom row: stimulation rate during the train.  Asterisk in C indicates time when some muscle action 
potentials became too small to measure latencies.  
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FIGURE 4.  Effects of repetitive stimulation on muscle action potential amplitudes, latencies, and muscle 
velocity recovery cycles.  A: Part of sequence of stimulating pulses, showing alternation between 1s trains at 
20 Hz, conditioning(c) and test(t) pairs, and test stimuli alone.  B-D: Average recordings from 26 normal 
control subjects (NC)(B), 9 patients with sodium channel myotonia (SCM)(C), and 8 patients with 
paramyotonia congenita (PMC)(D). Data are reported as mean (continuous line) ± standard error (broken 
lines).  Comparisons in (C) and (D) are against mean control values in gray.  Top two panels: Amplitude 
changes as a percentage of baseline of the first and last responses in the train respectively. Third panel: 
Latencies, expressed as % baseline value. Fourth panel: Relative refractory periods. Bottom panel: Peak 
early supernormality, expressed as % reduction in latency. Bars indicate 6m periods of intermittent 20 Hz 
stimulation. Asterisks in D indicate times when muscle action potentials in some PMC patients became too 
small to measure latencies.  
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